Florbetaben F18

Drug Profile

Florbetaben F18

Alternative Names: 18F-AV 1; 18F-AV1/ZK; [18F] florbetaben; AV-1; AV-1/ZK; BAY 94-9172; Florbetaben 18F; NeuraCeq; UNII-TLA7312TOI; ZK 6013443

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator Avid Radiopharmaceuticals
  • Developer Avid Radiopharmaceuticals; Bayer HealthCare Pharmaceuticals; Ci-Co Healthcare; PET Pharm Biotech; Piramal Enterprises
  • Class Aniline compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease
  • Phase I Mild cognitive impairment

Most Recent Events

  • 06 Sep 2016 Preregistration for Alzheimer's disease (Diagnosis) in Taiwan (IV)
  • 06 Sep 2016 Florbetaben F 18 licensed to PET Pharma Biotech for commercialisation in Taiwan
  • 02 Jun 2015 Registered for Alzheimer's disease (Diagnosis) in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top